POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R ...
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.133
https://www.valueinhealthjournal.com/article/S1098-3015(21)01928-8/fulltext
Title :
POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01928-8&doi=10.1016/j.jval.2021.11.133
First page :
Section Title :
Open access? :
No
Section Order :
10899